Hyperlipidemia
Conditions
Brief summary
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Interventions
DRUGAtorvastatin
Sponsors
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening * LDL-C \< 6.0 mmol/l * Triglyceride level \< 5.0 mmol/l.
Exclusion criteria
* Subjects receiving higher than usual maintenance doses of Lipid Lowering Therapy (LLT) at screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin. | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin. | — |
Countries
Switzerland
Outcome results
None listed